临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 1492-18-8

Calcium folinate

中文名称:亚叶酸钙
CAS号:1492-18-8
分子式: C20H21N7O7.Ca 分子量: 511.50
产品形式: calcium salt
研发状态: Recruiting
研发用途: Autism Spectrum Disorder; Language Disorders
研究机构: Southwest Autism Research & Resource Center; Autism Speaks; State University of New York - Downstate Medical Center
研发日期: October 8 2020
研发阶段: Phase 2
Calcium folinate (Leucovorin calcium, Folinic acid calcium salt, Wellcovorin) is a metabolically active, reduced form of folic acid that is rapidly absorbed and extensively metabolized in the liver to other folic acid derivatives.

CAS: 1490-04-6

Menthol

中文名称:薄荷脑
CAS号:1490-04-6
分子式: C10H20O 分子量: 156.26
产品形式: free base
研发状态: Recruiting
研发用途: Dyspnea; Chronic Obstructive Pulmonary Disease
研究机构: KU Leuven
研发日期: January 1 2023
研发阶段: Not Applicable
Menthyl alcohol is an organic compound made synthetically or obtained from peppermint or mint oils with flavoring and local anesthetic properties.

CAS: 1489389-18-5

CCT245737

中文名称:CCT245737游离态
CAS号:1489389-18-5
分子式: C16H16F3N7O 分子量: 379.34
产品形式: free base
研发状态: Completed
研发用途: Advanced Solid Tumors or Non-Hodgkin''s Lymphoma (NHL)
研究机构: Sierra Oncology LLC - a GSK company
研发日期: Jul-16
研发阶段: Phase 1 : Phase 2
CCT245737 (SRA737, PNT-737) is an orally active CHK1 inhibitor with The IC50 of 1.4 nM. It exhibits >1,000-fold selectivity against CHK2 and CDK1.

CAS: 1488363-78-5

Adomeglivant

中文名称:阿度格列凡
CAS号:1488363-78-5
分子式: C32H36F3NO4 分子量: 555.63
产品形式: free base
研发状态: Terminated
研发用途: Healthy
研究机构: Eli Lilly and Company
研发日期: Mar-15
研发阶段: Phase 1
Adomeglivant (LY2409021) is a potent and selective antagonist of glucagon receptor that is used as a chronic treatment for type 2 diabetes.

CAS: 148408-66-6

Docetaxel Trihydrate

中文名称:三水多烯紫杉醇
CAS号:148408-66-6
分子式: C43H53NO14.3H2O 分子量: 861.93
产品形式: Trihydrate
研发状态: Not yet recruiting
研发用途: Squamous Cell Non-small Cell Lung Cancer
研究机构: Shanghai JMT-Bio Inc.
研发日期: May 1 2024
研发阶段: Phase 2 : Phase 3
Docetaxel (RP56976, NSC 628503), an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.

CAS: 148244-82-0

Secoisolariciresinol diglucoside

中文名称:亚麻木酚素
CAS号:148244-82-0
分子式: C32H46O16 分子量: 686.70
产品形式: free base
研发状态: Completed
研发用途: Type 1 Diabetes Mellitus
研究机构: Adocia
研发日期: March 23 2021
研发阶段: Phase 2
Secoisolariciresinol diglucoside (SDG), a plant lignan isolated from flaxseed, has strong antioxidant activity, cardioprotective effects, reduces the blood levels of low-density lipoprotein cholesterol, and reduces the risk of hormone related cancer.